Allspring Global Investments Holdings LLC Lowers Stock Holdings in United Therapeutics Corporation (NASDAQ:UTHR)

Allspring Global Investments Holdings LLC decreased its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 2.2% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 82,764 shares of the biotechnology company's stock after selling 1,844 shares during the period. Allspring Global Investments Holdings LLC owned approximately 0.18% of United Therapeutics worth $25,399,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Cerity Partners LLC grew its position in United Therapeutics by 30.4% in the 4th quarter. Cerity Partners LLC now owns 11,588 shares of the biotechnology company's stock valued at $4,098,000 after buying an additional 2,702 shares during the last quarter. Korea Investment CORP boosted its holdings in shares of United Therapeutics by 6.2% in the fourth quarter. Korea Investment CORP now owns 39,289 shares of the biotechnology company's stock valued at $13,863,000 after acquiring an additional 2,300 shares in the last quarter. Nepsis Inc. boosted its holdings in shares of United Therapeutics by 6.7% in the first quarter. Nepsis Inc. now owns 58,574 shares of the biotechnology company's stock valued at $18,057,000 after acquiring an additional 3,653 shares in the last quarter. ExodusPoint Capital Management LP acquired a new position in shares of United Therapeutics during the fourth quarter worth about $1,899,000. Finally, Raymond James Financial Inc. purchased a new position in United Therapeutics during the fourth quarter worth about $18,257,000. Hedge funds and other institutional investors own 94.08% of the company's stock.

Insider Buying and Selling

In other news, EVP Paul A. Mahon sold 11,000 shares of the company's stock in a transaction on Thursday, June 26th. The stock was sold at an average price of $285.70, for a total value of $3,142,700.00. Following the sale, the executive vice president directly owned 36,781 shares in the company, valued at $10,508,331.70. This represents a 23.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Raymond Dwek sold 4,000 shares of the business's stock in a transaction dated Monday, April 7th. The shares were sold at an average price of $284.55, for a total transaction of $1,138,200.00. Following the completion of the transaction, the director directly owned 1,750 shares of the company's stock, valued at $497,962.50. The trade was a 69.57% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 80,681 shares of company stock worth $23,951,939. 10.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

UTHR has been the topic of a number of analyst reports. JPMorgan Chase & Co. lowered their price objective on United Therapeutics from $355.00 to $350.00 and set an "overweight" rating on the stock in a report on Thursday, May 1st. Wall Street Zen downgraded United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. Wells Fargo & Company reiterated an "equal weight" rating and issued a $314.00 price objective (down previously from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. Bank of America reduced their target price on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating for the company in a report on Wednesday, June 11th. Finally, UBS Group lowered their price target on shares of United Therapeutics from $410.00 to $385.00 and set a "buy" rating on the stock in a research note on Monday. Four research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, United Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $386.15.

United Therapeutics Stock Performance

NASDAQ:UTHR traded down $0.65 during mid-day trading on Thursday, hitting $294.57. 284,212 shares of the company's stock traded hands, compared to its average volume of 445,700. The company has a market cap of $13.29 billion, a PE ratio of 11.75, a price-to-earnings-growth ratio of 6.46 and a beta of 0.53. The firm's 50 day simple moving average is $301.15 and its 200 day simple moving average is $323.11. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, topping analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a net margin of 40.44% and a return on equity of 19.33%. The business had revenue of $794.40 million during the quarter, compared to analysts' expectations of $726.82 million. During the same period last year, the company posted $6.17 EPS. The company's revenue was up 17.2% on a year-over-year basis. On average, research analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.